Why Alkegen's Opt-Out Releases Were OK Under Purdue, Ebix
By Alex Wittenberg · September 4, 2026, 8:44 PM EDT
Specialty materials maker Alkegen's defeat of a challenge to legal releases in its Chapter 11 plan offers more clarity around what constitutes consent under the U.S. Supreme Court's Purdue Pharma decision,...
To view the full article, register now.